Table 1.
Analytical analysis of demographics and clinical characteristics of 139 cardiovascular patient treated with warfarin at the Queen Alia Heart Institute.
| Category | Subcategory | Extensive Metabolizera | Good Metabolizersb | Poor Metabolizersc | P value* |
|---|---|---|---|---|---|
| Demographics | Patients (N, %) | (25/139) 18.0% | (88/139) 63.3% | (26/139) 18.7% | |
| Aged [years] | 47.6 [17.7] | 53.2 [15.3] | 54.2 [18.4] | 0.457 | |
| BMId | 26.7 [4.0] | 27.6 [4.8] | 28.0 [6.6] | 0.641 | |
| Smoking (%) | (12/25) 48.0% | (18/88) 31.8% | (12/26) 46.2% | 0.043 | |
| Male | (17/25) 68.0% | (49/88) 55.7% | (17/26) 65.4% | 0.304 | |
| Female | (8/25) 32.0% | (39/88) 44.3% | (9/26) 34.6% | ||
| Concomitant Disease | Co morbidity | (15/25) 60.0% | (54/88) 61.4% | (13/26) 50.0% | 0.578 |
| Hypertension | (6/25) 24.0% | (35/88) 39.8% | (10/26) 38.5% | 0.425 | |
| Diabetes mellitus | (9/25) 36.0% | (16/88) 18.2% | (6/26) 23.1% | 0.124 | |
| CHDe | (8/25) 32.0% | (17/88) 19.3% | (6/26) 23.1% | 0.329 | |
| Thyroid | (1/25) 4.0% | (2/88) 2.3% | (0/26) 0.0% | 0.596 | |
| Lipid | (1/25) 4.0% | (7/88) 8.0% | (1/26) 3.8% | 0.673 | |
| Medication | Aspirin | (18/25) 72.0% | (57/88) 64.8% | (17/26) 65.4% | 0.600 |
| Indication of Treatment | MVRf | (5/25) 20.0% | (9/88) 10.3% | (6/26) 23.1% | 0.127 |
| AVRg | (7/25) 28.0% | (31/88) 35.2% | (2/26) 7.7% | ||
| AFh | (6/25) 24.0% | (14/88) 15.9% | (5/26) 19.2% | ||
| DVRi | (6/25) 24.0% | (15/88) 17.0% | (9/26) 34.6% | ||
| Others | (1/25) 4.0% | (19/88) 21.6% | (4/26) 15.4% | ||
| Target INR | 2–3 | (10/25) 40.0% | (37/88) 42.0% | (11/26) 42.3% | 0.998 |
| 2.5–3.5 | (15/25) 60.0% | (51/88) 58.0% | (15/26) 57.7% | ||
| Mean INRd | 2.4 [0.53] | 2.6 [0.64] | 2.9 [0.56] | 0.021 | |
*
P value < 0.05 is considered significant.
a
Extensive metabloizer or warfarin resistance group (required high warfarin dose > 49 mg/week).
b
Moderate metabolizer or warfarin response group (required average warfarin dose between 21 and 49 mg/week).
c
Poor metabolizer group or warfarin-sensitive group (required minimum warfarin dose < 21 mg/week).
d
Mean Standard deviation in square brackets.
e
CHD: Chronic heart disease.
f
MVR:Mitral valve replacement.
g
AVR: Aortic valve replacement.
h
AF: Atrial Fibrillation.
i
DVR: Double valve replacement.